Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144690 · ClinicalTrials.gov registry record · Phase 2
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Phase 2 study of Epilepsy, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
NCT00144690: Completed Phase 2 study of Epilepsy, sponsored by Eisai.
NCT00144690 is a Phase 2 study of Epilepsy that has completed, run by Eisai. The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00144690, a Phase 2 study of Epilepsy, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5
- Study locations
Study Summary
The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized seizures). The secondary objectives are to evaluate the safety, efficacy, concentration-efficacy relationship, and pharmacokinetics of E2007 and the effects of E2007 on the Profile of Mood States (POMS) test.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG E2007 (perampanel)
Study Locations (5)
Arkansas
- Dept. of Neuro Surgery - Little Rock
Florida
- USF Physicians Group - Tampa
Michigan
- Clinical Trials - Detroit
Ohio
- Medical College of Ohio Comprehensive Epilepsy Ctr. - Toledo
Tennessee
- Vanderbilt University Medical Ctr. - Nashville
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00144690 record still lists
NCT00144690 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00144690 lists 5 locations in 5 states (Arkansas, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT00144690 about?
NCT00144690 is a clinical study titled "E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures". The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized seizures). The secondary objectives are to evaluate the safety, efficacy, con...
What is the current status of trial NCT00144690?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-03. Estimated completion is 2007-02.
What conditions does trial NCT00144690 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00144690?
The interventions under investigation include: Placebo (DRUG), E2007 (perampanel) (DRUG).
Who is sponsoring clinical trial NCT00144690?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00144690 being conducted?
This trial has 5 study locations across Arkansas, Florida, Michigan, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia